Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
about
Integration of Mitochondrial Targeting for Molecular Cancer TherapeuticsMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsPathways and therapeutic targets in melanomaEffects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Metabolic rewiring in melanomaMetformin in obesity, cancer and aging: addressing controversiesA novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent mannerMetformin therapy and prostate cancer risk: a meta-analysis of observational studies.Combined regimen of photodynamic therapy mediated by Gallium phthalocyanine chloride and Metformin enhances anti-melanoma efficacymTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenibRAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.Metabolic roles of AMPK and metformin in cancer cells.Metformin targets multiple signaling pathways in cancer.Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cellsDoes use of metformin protect against cancer in Type 2 diabetes mellitus?Vemurafenib: in unresectable or metastatic melanoma.Targeting SREBP-1-driven lipid metabolism to treat cancerIs it time to test biguanide metformin in the treatment of melanoma?Metformin Synergistically Potentiates the Antitumor Effects of Imatinib in Colorectal Cancer CellsTime-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK.The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells.Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration.Combinational strategies of metformin and chemotherapy in cancers.Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition.Association between metformin use and risk of prostate cancer and its grade.Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit.Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor).Metformin: Focus on Melanoma
P2860
Q26771751-AC16B43F-7CE2-4209-B3D1-893A0B6D4EBEQ26795735-31C833CE-F0E2-4600-8051-A2D65A9051B6Q26865736-AEEA3C3C-DDD7-4584-85BA-5E7E8AC4E1B8Q27852994-079EB75B-5411-4593-8694-8D94E586356EQ27853104-0848957F-DAE1-4845-B899-01AFE596698AQ28069081-EBBF893A-5C3B-4745-A44B-2E9B52C4AC87Q28480735-D7194E96-1694-4F2E-A1F1-9894BFA3C5F8Q28817145-ED4133A9-CCFB-45FE-87E1-A7E5F18A0EA7Q36182935-C9FCE8A9-2F3D-41BD-944E-0AC5701F8AB6Q36302221-FD904534-5686-4740-8002-B48DE401B702Q36545458-C30037EF-6CE0-447A-AA5A-1D28E2C4E587Q37048053-3489C622-0007-45EF-9686-D7023F148C85Q37318124-F27979E5-D759-401E-BD2F-3E2491DE4CB4Q37462711-68E6695A-35C5-4008-A8D2-8E179830D975Q37609790-0D6F89DB-C061-4D51-99CB-8846BD5659FCQ37625891-B2F2A99D-1721-4DE5-8782-5B80F5F231AEQ37736262-C87E0B2E-9CE7-4E17-8702-44F12CC0D4E3Q38001521-3288D240-D2C1-4395-8E6E-F67E8FB6FD5CQ38040456-DF7BD9BF-236E-45C8-B092-F9D965E76FD2Q38121980-4E3AB6A4-AE90-41DF-9D21-BAA4896BF3B9Q38215034-1FAE8C06-CCEA-4192-8ED2-A865C4668DB2Q38635672-FDACA1BD-4355-476B-80AA-6DE982A8D3E8Q38716887-5709CBE0-E407-474E-B257-FD75B945EF93Q38739247-FFD6A6FC-782D-462D-96D1-0A00B50BFE1DQ38815463-5D7352A4-B8BE-46B1-8E82-236C5E566AA5Q38818730-458401A6-E7AC-481B-88A8-451F135A849CQ38849622-05BF5F13-69B2-4B1E-A862-41CDAB9A36B1Q42867540-0698F9DC-5F7D-43BC-BBC4-A550602E9A7DQ43566439-4E357A8A-7EAB-4792-B0C1-0179889AB280Q47759599-C2F2C0B7-FDA3-4BBA-8EFD-386A98A0E98CQ48312483-19F2AADE-3A79-468C-8D44-6BD64ADFCF51Q55492453-0AE07FF8-7696-488B-BB0E-BC410D9627C9Q58728932-740CDA77-EAD6-4D67-88F4-E5912DF930B1
P2860
Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Combination therapy with vemur ...... ith distinct driver mutations.
@en
Combination therapy with vemurafenib
@nl
type
label
Combination therapy with vemur ...... ith distinct driver mutations.
@en
Combination therapy with vemurafenib
@nl
prefLabel
Combination therapy with vemur ...... ith distinct driver mutations.
@en
Combination therapy with vemurafenib
@nl
P2093
P2860
P356
P1476
Combination therapy with vemur ...... ith distinct driver mutations.
@en
P2093
Antoni Ribas
Begonya Comin-Anduix
Charles Ng
Deliang Guo
Doug Matsunaga
Erika von Euw
Franziska Niehr
Hooman Sazegar
John A Glaspy
Juan A Recio
P2860
P2888
P356
10.1186/1479-5876-9-76
P577
2011-05-24T00:00:00Z
P5875
P6179
1017446712